Clinical Trial Update: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous CD19-specific CAR T cells (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma, chronic lymphocytic leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• TBI-2001 (Autologous CD19-specific CAR T cells)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 1 | Status: RECRUITING